Feedback / Questions
camidanlumab tesirine (ADCT-301) - Genmab, ADC Therapeutics
https://www.businesswire.com/news/home/20220610005073/en/ADC-Therapeutics-Announces-Results-from-Pivotal-Phase-2-Clinical-Trial-of-Camidanlumab-Tesirine-Cami-in-Relapsed-or-Refractory-Hodgkin-Lymphoma
Jun 10, 2022
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next